Zelira Therapeutics

(OTC) ZLDAF

Current Price$0.35

Market Cap$4.16M

Since IPO (2017)-95%

5 Year-95%

1 Year+17%

1 Month+6%

Zelira Therapeutics Financials at a Glance

Market Cap

$4.16M

Revenue (TTM)

$95.61K

Net Income (TTM)

$40.20M

EPS (TTM)

$-0.21

P/E Ratio

-1.70

Dividend

$0.00

Beta (Volatility)

2.48 (High)

Dividend

$0.00

Beta (Volatility)

2.48 (High)

Price

$0.35

Volume

114

Open

$0.35

Price

$0.35

Volume

114

Open

$0.35

Previous Close

$0.35

Daily Range

$0.35 - $0.35

52-Week Range

$0.20 - $0.42

Dividend

$0.00

Beta (Volatility)

2.48 (High)

Price

$0.35

Volume

114

Open

$0.35

Previous Close

$0.35

Daily Range

$0.35 - $0.35

52-Week Range

$0.20 - $0.42

ZLDAF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Zelira Therapeutics

Industry

Pharmaceuticals

Sector

Health Care

CEO

Oludare Odumosu, PhD

Website

zeliratx.com

Headquarters

Perth, WA 6000, AU

ZLDAF Financials

Key Financial Metrics (TTM)

Gross Margin

-1226%

Operating Margin

-6638%

Net Income Margin

-5539%

Return on Equity

Return on Capital

Return on Assets

-3%

Earnings Yield

-58.82%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.16M

Shares Outstanding

11.90M

Volume

114

Avg. Volume

26.333

Financials (TTM)

Gross Profit

$802.95K

Operating Income

$3.95M

EBITDA

$4.05M

Operating Cash Flow

$4.91M

Capital Expenditure

$0.00

Free Cash Flow

$4.91M

Cash & ST Invst.

$5.66K

Total Debt

$2.14M

Zelira Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$800.84K

+32.3%

Gross Margin

0.00%

N/A

Market Cap

$4.16M

N/A

Market Cap/Employee

$520.50K

N/A

Employees

N/A

Net Income

$1.22M

+47.0%

EBITDA

$2.68M

+22.0%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$2.14M

-632.2%

Accounts Receivable

$4.69K

+529.2%

Inventory

$477.91K

-68.7%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$2.14M

+1402.5%

Return on Assets

-2.79%

N/A

Return on Invested Capital

1.01%

N/A

Free Cash Flow

$2.27M

+37.6%

Operating Cash Flow

$2.27M

+37.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PKTXProtoKinetix, Incorporated

PKTXProtoKinetix, Incorporated$0.01+0.00%

APLIFAppili Therapeutics Inc.

APLIFAppili Therapeutics Inc.$0.01+3.45%

ARUXFAcrux Limited

ARUXFAcrux Limited$0.00+0.00%

AXIMAXIM Biotechnologies, Inc.

AXIMAXIM Biotechnologies, Inc.$0.01-16.67%

SIGYSigyn Therapeutics, Inc.

SIGYSigyn Therapeutics, Inc.$0.05+11.36%

REPCFRepliCel Life Sciences Inc.

REPCFRepliCel Life Sciences Inc.$0.00+0.00%

RDDTFRadient Technologies Inc.

RDDTFRadient Technologies Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$99.62+0.05%

NOKNokia

NOKNokia$13.30+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.07+0.05%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.70+0.01%

AAPLApple

AAPLApple$280.14+0.03%

SOFISoFi Technologies

SOFISoFi Technologies$16.43+0.02%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$65.30+0.03%

Questions About ZLDAF

What is the current price of Zelira Therapeutics?

Zelira Therapeutics is trading at $0.35 per share.

What is the 52-week range for Zelira Therapeutics?

Over the past 52 weeks, Zelira Therapeutics has traded between $0.20 and $0.42.

How much debt does Zelira Therapeutics have?

As of the most recent reporting period, Zelira Therapeutics reported total debt of $1.40M.

How much cash does Zelira Therapeutics have on hand?

Zelira Therapeutics reported $3,711.247 in cash and cash equivalents in its most recent financial results.

What is Zelira Therapeutics’s dividend yield?

Zelira Therapeutics does not currently have a dividend yield.

Zelira Therapeutics

Zelira Therapeutics Financials at a Glance

ZLDAF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Zelira Therapeutics

ZLDAF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Zelira Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ZLDAF

What is the current price of Zelira Therapeutics?

What is the 52-week range for Zelira Therapeutics?

How much debt does Zelira Therapeutics have?

How much cash does Zelira Therapeutics have on hand?

What is Zelira Therapeutics’s dividend yield?

Premium Investing Services